2019
DOI: 10.2967/jnumed.119.229062
|View full text |Cite
|
Sign up to set email alerts
|

No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy

Abstract: The aim of this study was to determine if additional 18 F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate-or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels , 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level $ 0.2 ng/mL was bioch… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
17
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 14 publications
(17 citation statements)
references
References 13 publications
0
17
0
Order By: Relevance
“…A minimum of 12 months of clinical and laboratory follow-up was required. Patients with PSA < 0.1 ng/mL after radical prostatectomy without any systemic treatment were categorized as having no bone metastases at the time of staging [16].…”
Section: Best Valuable Comparatormentioning
confidence: 99%
“…A minimum of 12 months of clinical and laboratory follow-up was required. Patients with PSA < 0.1 ng/mL after radical prostatectomy without any systemic treatment were categorized as having no bone metastases at the time of staging [16].…”
Section: Best Valuable Comparatormentioning
confidence: 99%
“…We included patients with PCa who had participated in 4 prospective studies at our department (6,(11)(12)(13). All patients had undergone 18 F-NaF PET/CT as part of the study-related procedures.…”
Section: Patientsmentioning
confidence: 99%
“…Patients were categorized as having biochemical recurrence and castration-resistant PCa on the basis of the criteria from the European Association of Urology (2,16). In most patients (211/219, 96%), a final diagnosis for the presence or absence of bone metastases was available from the initial study in which the patient participated (6,(11)(12)(13). In short, in every study a final diagnosis on a patient level was achieved by combining all clinical data, biochemical data, and imaging conducted before inclusion in the study and during follow-up.…”
Section: Clinical Data and Final Diagnosis Of Metastatic Statusmentioning
confidence: 99%
“…However, a recent study demonstrated that 18 F-NaF PET/ CT was unable to detect bone metastases within 24 mo of radical prostatectomy in patients with biochemical failure. The report on this study concluded that staging with 18 F-NaF PET/CT does not have a superior prognostic value in patients with normal bone scan results in terms of improved patient-related outcomes after radical prostatectomy (48). PET offers a higher resolution, and as a result, 18 F-NaF PET is considered more sensitive than the traditionally used 99m Tc-MDP bone scans to detect the minimal osteoblastic activity associated with lytic bone metastases (27,38,49).…”
Section: Comparison 18 F-naf Versus 99m Tc-mdpmentioning
confidence: 89%